Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-60
SponsorPaul Szabolcs
About this trial
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
Eligibility criteria
Qualifiers
Subject must be able to understand and provide informed consent.
Male or female, 18 through 60 years old, inclusive, at the time of informed consent.
Meet criteria for UNOS listing for lung transplantation.
Pulmonary Fibrosis
Disqualifiers
Inability or unwillingness of a participant to give written informed consent or comply with study protocol.
Patients who have underlying malignant conditions.
Patients who have non-malignant conditions not requiring BMT.
HIV positive by serology or PCR, HTLV positive by serology. If HTLV serology is positive, it will be confirmed by nucleic acid testing (NAT). If HTLV NAT is negative, subject will remain eligible regardless of HTLV serology result.
Trial design
Treatments tested in this trial
- CD3/CD19 negative hematopoietic stem cells
- Rituximab
- Alemtuzumab
- Fludarabine
- Thiotepa
- G-CSF
- Hydroxyurea
Treatment groups
8 Participants
are divided into 1 treatment groupSponsors and collaborators
Paul Szabolcs
Lead sponsor
University of Pittsburgh
Sponsor institution
Source ClinicalTrials.gov